(Q33627259)

28 July 2017

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis (English)

1 reference

28 July 2017

0 references

1 reference

Per Soelberg Sørensen

15

object named as

Per Soelberg Sørensen

1 reference

28 July 2017

Antonio Bertolotto

2

0 references

Hans-Peter Hartung

5

object named as

Hans-Peter Hartung

1 reference

28 July 2017

4

Gavin Giovannoni

1 reference

28 July 2017

7

Joep Killestein

1 reference

28 July 2017

1

Chris H Polman

1 reference

28 July 2017

Florian Deisenhammer

3

1 reference

28 July 2017

Bernhard Hemmer

6

1 reference

28 July 2017

Henry F McFarland

8

1 reference

28 July 2017

Joel Oger

9

1 reference

28 July 2017

Andrew R Pachner

10

1 reference

28 July 2017

John Petkau

11

1 reference

28 July 2017

Anthony T Reder

12

1 reference

28 July 2017

Stephen C Reingold

13

1 reference

28 July 2017

Huub Schellekens

14

1 reference

28 July 2017

1 July 2010

1 reference

28 July 2017

1 reference

28 July 2017

9

1 reference

28 July 2017

740-750

1 reference

28 July 2017

7

1 reference

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Predictive markers for response to interferon therapy in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Antibodies against interferon-beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

The challenge of follow-on biologics for treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970103-4

7 January 2021

10.1016/S1474-4422(10)70103-4

Identifiers

DOI

1 reference

28 July 2017

1 reference